Graft persistence effectively induces and maintains donor-specific unresponsiveness

The Journal of Surgical Research
H NishinakaM Tanaka

Abstract

In the present study we attempted to evaluate the role of the graft as an alloantigen in induction and maintenance of donor-specific prolongation of allograft survival by short course(s) of FK506 treatment in rat heart transplantation. Materials and methods. In the WKA/Qdj-to-LEW combination group, FK506 (3 mg/kg/day, 7 days, s.c.) was administered from Day 0 after cardiac transplantation. A second WKA/ Qdj cardiac graft was transplanted on Day 14 into the LEW recipient after removal of the first graft on Day 3 or Day 7. In other groups an additional course of FK506 (3 mg/kg/day, 7 days, s.c.) was given from Day 35. A second WKA/Qdj cardiac graft was transplanted on Day 49 into the LEW recipient after removal of the first graft on Day 7 or Day 28. A short course of FK506 treatment allowed for survival prolongation of a cardiac allograft [mean survival time (MST) = 42.8 days]. Removal of the first graft on Day 7 (MST = 16.4 days) but not on Day 3 (MST = 10.2 days) caused donor-specific prolongation of the second allograft survival, which was significantly shorter than that in the recipient without the graftectomy (MST = 32.8 days). When graftectomy was performed on Day 3, there were immunohistochemically detectable levels of don...Continue Reading

Citations

Mar 29, 2001·Transfusion·D J Triulzi, M A Nalesnik
Apr 1, 2000·Transplant International : Official Journal of the European Society for Organ Transplantation·D MeyerK Ulrichs
Jun 7, 2008·Seminars in Dialysis·Jeffrey PerlSarbjit V Jassal
Jul 10, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·O JohnstonJ S Gill
Jun 28, 2011·Scandinavian Journal of Urology and Nephrology·Bernardo Faria, Anabela Rodrigues

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Digestive Diseases and Sciences
Y YamaguchiM Ogawa
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
Jeffrey PerlS Vanita Jassal
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
Hadassa MadarAvry Chagnac
© 2021 Meta ULC. All rights reserved